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Summary
Background Between 62 000 and 77 000 women die annually from pre-eclampsia and eclampsia. Prompt delivery, 
preferably by the vaginal route, is vital for good maternal and neonatal outcomes. Two low-cost interventions—
low-dose oral misoprostol tablets and transcervical Foley catheterisation—are already used in low-resource settings. 
We aimed to compare the relative risks and benefits of these interventions.
Methods We undertook this multicentre, open-label, randomised controlled trial in two public hospitals in Nagpur, India. 
Women (aged ≥18 years) who were at 20 weeks’ gestation or later with a live fetus and required delivery as a result of pre-
eclampsia or hypertension were randomly assigned (1:1), via computer-generated block randomisation (block sizes of four, 
six, and eight) with concealment by use of opaque, sequentially numbered, sealed envelopes, to receive labour induction 
with either oral misoprostol 25 µg every 2 h (maximum of 12 doses) or a transcervical Foley catheter (silicone, size 18 F with 
30 mL balloon). Randomisation was stratified by study centre. The catheter remained in place until active labour started, the 
catheter fell out, or 12 h had elapsed. If the catheter did not fall out within 12 h, induction continued with artificial membrane 
rupture and oxytocin, administered through a micro-drip gravity infusion set. Fetal monitoring was by intermittent 
auscultation. The primary outcome was vaginal birth within 24 h. Due to the nature of the interventions, masking of 
participants, study investigators, and care providers to group allocation was not possible. We analysed by intention to treat. 
This trial is registered with ClinicalTrials.gov, number NCT01801410.
Findings Between Dec 20, 2013, and June 29, 2015, we randomly assigned 602 women to induction with misoprostol 
(n=302) or the Foley catheter (n=300; intention-to-treat population). Vaginal birth within 24 h was more common in 
women in the misoprostol group than in the Foley catheter group (172 [57·0%] vs 141 [47·0%] women; absolute risk 
difference 10·0%, 95% CI 2·0–17·9; p=0·0136). Rates of uterine hyperstimulation were low in both the misoprostol and 
Foley catheter groups (two [0·7%] vs one [0·3%] cases; absolute risk difference 0·3%, 95% CI –0·8 to 1·5; p=0·566) and 
neonatal deaths did not differ significantly between groups (six [2·0%] vs three [1·0%] neonatal deaths; 1·0, –1·04 to 2·97; 
p=0·322). 17 serious adverse events (3%) were reported during the study: one case of intrapartum convulsion and one 
case of disseminated intravascular coagulation (both in the Foley group); ten perinatal deaths, including two stillbirths 
(both in the Foley catheter group) and eight neonatal deaths (n=5 in the misoprostol group and n=3 in the Foley catheter 
group); and five of neonatal morbidity, comprising birth asphyxia (n=3), septicaemia (n=1), and neonatal convulsion 
(n=1).
Interpretation Oral misoprostol was more effective than transcervical Foley catheterisation for induction of labour in 
women with pre-eclampsia or hypertension. Future studies are required to assess whether oxytocin augmentation 
following misoprostol can be replaced by regular doses of oral misoprostol tablets.
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Introduction
Hypertensive disorders, including pre-eclampsia, are the 
most common medical complications of pregnancy, 
affecting 10% of pregnancies. Pre-eclampsia and 
eclampsia are leading causes of maternal mortality, 
accounting for about 14% of the 303 000 global maternal 
deaths annually.1,2 Effective care, including treatment 
with magnesium sulphate and antihypertensive drugs, 
can reduce maternal morbidity and mortality; however, 
timely delivery, preferably by the vaginal route, is the 
only definitive cure and is vital to achieve good maternal 
and neonatal outcomes. Two low-cost cervical ripening 
methods—low-dose oral misoprostol and the Foley 
catheter—have been recommended for use in low-
resource settings, where most of the morbidity and 
mortality associated with pre-eclampsia occurs.3
Misoprostol, the orally active and heat-stable 
prostaglandin E1 analogue, has been used for labour 
induction for almost 20 years. For labour induction, 
misoprostol is commonly administered vaginally. 
However, a systematic review4 of studies that compared 
oral and vaginal low-dose misoprostol found that women 
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using oral misoprostol were significantly less likely to 
have uterine hyperstimulation with changes in fetal heart 
rate (2% vs 13%; relative risk 0·19, 95% CI 0·08–0·46), 
but no significant differences were reported in other 
outcomes. A Cochrane review5 included all studies that 
used oral misoprostol for labour induction, irrespective 
of dose. Most of the low-dose studies used 20 µg of oral 
misoprostol solution. The review concluded that “given 
that safety is the primary concern, the oral regimens are 
recommended over vaginal regimens. This is especially 
important in situations where the risk of ascending 
infection is high and the lack of staff means that women 
cannot be intensely monitored.”5 This finding is also 
supported by a network meta-analysis6 of various 
methods that use prostaglandin induction.
Although oral misoprostol is very effective, all 
induction methods can cause uterine hyperstimulation, 
which in turn can cause fetal hypoxia. The risk of hypoxic 
damage is increased in pre-eclampsia, when babies 
might be born prematurely or be affected by intrauterine 
growth restriction. In low-resource settings, where access 
to intrapartum fetal monitoring might be poor, avoidance 
of hyperstimulation is crucial.
The Foley balloon catheter offers an alternative low-
cost method for labour induction, which could be safer 
for the fetus than using current standard methods. 
Induction with the Foley catheter seems to be as effective 
as current methods, but with lower rates of uterine 
hyperstimulation and better fetal outcomes.7,8 Results of 
studies have shown no increase in rates of infection.9 
Although this method appears promising, few 
(eight of 30) of the studies using the Foley catheter were 
done in low-resource settings.
These two methods, the Foley catheter and low-dose 
oral misoprostol, seem to be the optimal choices for low-
resource settings, but only a few direct comparisons have 
been done between them. A multicentre Dutch study10 
compared Foley balloon catheter induction with oral 
misoprostol. The dose was 50 µg misoprostol every 4 h, a 
regimen that has largely been superseded by the low-dose 
1–2 h administration, which is more in keeping with the 
pharmacokinetic profile for oral misoprostol. The 
1859 participants were all at term with an unripe cervix 
and an intact membrane, but had a wide variety of 
indications for induction of labour. The study found no 
differences between groups in any of the major outcomes; 
Research in context
Evidence before this study
We searched PubMed and the Cochrane Database of Clinical 
Trials (CENTRAL) using the search terms “oral misoprostol”, 
“induction of labour”, and “catheter” and MeSH terms and 
appropriate variations, with no language restrictions for studies 
from Jan 1, 1980, to Jan 1, 2013. We used standard Cochrane 
methods to assess quality. The Cochrane Collaboration did a 
systematic review in 2012 of the effectiveness of Foley catheter 
for the induction of labour. From these sources we identified 
just one small study in which 151 women were randomly 
assigned to receive Foley catheterisation or oral misoprostol 
(50 µg every 4 h). The investigators reported no significant 
differences between groups in any of the outcomes. The 
optimal misoprostol dose is not known. Only one comparative 
dose-finding study exists, in which oral misoprostol 50 µg every 
4 h was compared with 20 µg given every hour, in a 
double-blind study of 64 women undergoing induction. No 
differences were found in any of the outcomes. However, 
evidence from the Cochrane review of oral misoprostol for 
labour induction suggests that outcomes might be best with 
the use of low-dose misoprostol (20–25 µg) given every 2 h, 
and this is the dose recommended in the WHO induction of 
labour guidelines. WHO guidelines also suggest the use of the 
Foley catheter for induction as an alternative.
Added value of this study
To our knowledge, this study is the first to directly compare the 
two regimens for labour induction recommended by WHO: 
low-dose oral misoprostol (25 µg) and the Foley catheter (both 
followed by membrane rupture and oxytocin infusion). 
The study was also done in the highest risk women (those with 
hypertension who are more likely to be primigravid, preterm, 
and have growth-restricted babies) and setting (a government 
facility without routine electronic fetal monitoring or electronic 
drip counters for the oxytocin). We found that oral misoprostol 
25 µg tablets given every 2 h were more effective than Foley 
catheter induction for a range of measures, including vaginal 
birth rate, speed of induction, and women’s satisfaction. Adverse 
maternal or neonatal outcomes did not differ between groups.
Implications of all the available evidence
Since we did our study, a large multicentre study has been 
reported, in which 1859 women were randomly assigned to 
receive labour induction by either Foley catheter or 50 µg oral 
misoprostol every 4 h. This dose is higher than that used in our 
study, but no differences were reported in the main maternal or 
neonatal outcomes assessed. Our study showed better 
outcomes with the new 25 µg misoprostol tablets than with the 
Foley catheter, especially for satisfaction and vaginal birth rate. 
These findings reinforce those from the Cochrane review of oral 
misoprostol for labour induction, in which the 20–25 µg doses 
of oral misoprostol were associated with lower rates of 
caesarean section delivery than was induction with either 
higher oral misoprostol doses or standard induction methods. 
Therefore, we believe that low-dose oral misoprostol (25 µg) 
given every 2 h is the optimal method for labour induction. 
Some clinicians give the oral misoprostol during active labour 
(rather than replacing it with an oxytocin infusion), but 
whether this method is as effective and safe remains to be seen.
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however, general satisfaction with labour was greater in 
women whose labours were induced with misoprostol.11
Labour induction for women with hypertension or 
pre-eclampsia is a crucial intervention in low-resource 
settings because it is one of the few indications for which 
induction is done primarily for the safety of the mother. 
The induction process is made more difficult and 
dangerous because nulliparity, preterm gestations, and 
undiagnosed fetal growth restriction are common. 
Moreover, after cervical ripening with the Foley catheter, 
many women require oxytocin infusions, which can be 
risky in settings with no access to electronic infusion 
pumps. All these factors increase the risk to mother and 
baby, especially when antenatal and intrapartum fetal 
monitoring is scarce.
We undertook the INFORM trial to compare the 
efficacy, safety, acceptability, and cost-effectiveness of 
misoprostol treatment with Foley balloon catheter 
induction of labour in women with gestational 
hypertension in a low-resource setting.
Methods
Study design and participants
This multicentre, open-label, randomised controlled trial 
was undertaken at two public hospitals in Nagpur, India: 
Government Medical College and Daga Women’s Hospital. 
Participants were informed about the study by their 
doctors when the decision for induction of labour was 
made, and were enrolled by research staff on the labour 
ward on the day of induction. We included women who 
were at least 18 years of age, at 20 weeks’ gestation or later 
with a live fetus, and in whom the decision had been made 
to induce vaginal birth because of pre-eclampsia or 
hypertension. The original protocol was changed from 
“pre-eclampsia or uncontrolled hypertension” when it 
became clear that induction for hypertension was often 
done without the aid of urinary protein analysis or 
prolonged assessment. We excluded women who were 
unable to give informed consent, those with a history of 
caesarean section, multiple pregnancy, ruptured 
membranes, clinically diagnosed chorioamnionitis, or a 
history of allergy to misoprostol.
The study was approved by the Research Ethics 
Committees at Government Medical College, Nagpur, 
and the University of Liverpool, UK. As required by the 
Drug Controller General of India, participants provided 
both written and video-recorded oral consent. The study 
was monitored by independent steering and data 
monitoring committees. The full protocol has been 
previously published elsewhere.12
Randomisation and masking
After the participant provided informed consent, research 
staff opened a sequentially numbered, sealed, opaque 
envelope containing the participant’s group assignment 
and participants were randomly allocated, in a 1:1 ratio, to 
receive either cervical ripening with transcervical Foley 
catheterisation or oral misoprostol tablets. The envelopes 
were generated by staff at Gynuity Health Projects 
(New York, NY, USA) by use of a randomisation code 
provided independently by the trial statistician on the 
basis of computer-generated pseudorandom numbers, 
with block sizes of four, six, and eight. Randomisation was 
stratified by centre. Due to the nature of the interventions, 
masking of participants, study investigators, and care 
providers to group allocation was not possible.
Procedures
Before randomisation, the resident doctor did a digital 
examination to establish a baseline Bishop score13 and 
cervical dilatation. In the two busy government hospitals 
in which we did the study, the decision to induce labour 
was made pragmatically based on gestation and the 
presence of hypertension. Proteinuria was assessed 
when possible, depending on the availability of urinary 
protein dipsticks. Women allocated to the Foley catheter 
group underwent induction with a transcervical Foley 
catheter (silicone, size 18F with 30 mL balloon). The 
catheter was placed either by visualisation with the help 
of a speculum or blindly, filled with 30 mL saline, and 
strapped to the thigh under gentle tension. The catheter 
remained in place until it was expelled when active 
labour started or until 12 h had elapsed. If the Foley 
catheter fell out within 12 h, the membranes were 
ruptured and an oxytocin infusion was started. If the 
Foley catheter did not fall out within 12 h, it was removed 
at 12 h and oxytocin started with an artificial rupture of 
membrane when possible.
Women allocated to the misoprostol group were induced 
with oral misoprostol tablets (25 µg; Cipla, Mumbai, 
India) given every 2 h for a maximum of 12 doses or until 
active labour started. In primigravid women in whom 
contractions had not started after two doses, the dose 
could be increased to 50 µg every 2 h. Once in labour 
(defined as regular, painful contractions, with a cervical 
dilatation of at least 4 cm), no more misoprostol was given 
and artificial membrane rupture or oxytocin infusion was 
used as clinically indicated. In both groups, if labour had 
not started after 24 h, the induction was classified as failed 
and the decision on further management was made by the 
clinical team.
For women in both groups, temperature and uterine 
tone and contraction frequency were assessed every 2 h 
and a vaginal examination was done every 4 h to assess 
cervical dilatation and Bishop score. Oxytocin infusion 
was given with a micro-drip gravity infusion set, 
monitored by calculation of the drops per min. One unit 
of oxytocin was injected in 500 mL of Ringer’s lactate, 
started at a rate of 2 mU/min (15 drops per min), and 
increased every 30 min by 2 mU/min until three to four 
contractions happened every 10 min. Intermittent fetal 
monitoring was done with a Pinard stethoscope or a 
handheld fetal Doppler every hour before active labour 
and then every 15–30 min during the active stage of 
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labour. All participants were monitored by the research 
staff on a one-to-one basis. Magnesium sulphate and 
antihypertensives were given to participants with severe 
pre-eclampsia, as per the hospital protocol. Participant 
data, including demographic characteristics, medical and 
pregnancy history, labour course, and outcomes, were 
collected by the research staff.
Resident staff in both the participating hospitals were 
familiar with the use of a Foley catheter. However, they 
underwent brief training in placement of the Foley 
catheter before the start of the trial to ensure the insertion 
method was uniform.
Outcomes
The primary outcome was vaginal birth within 24 h. 
Secondary outcomes included measures of efficacy of the 
induction process assessed by the induction to birth 
interval (in vaginal births, caesarean sections, and all 
births), vaginal births within 12 h, cervix unchanged at 
12 h and 24 h, need for oxytocin augmentation, and time 
from randomisation to start of induction and birth. 
Secondary outcomes for women in the misoprostol group 
also included assessment of the total dose of misoprostol 
used and the number of participants given a 50 µg dose. 
We also assessed maternal complications, including 
uterine tachysystole (defined as more than five 
contractions in 10 min); uterine hypertonus (defined as a 
single contraction lasting longer than 2 min); caesarean 
section; uterine rupture; instrumental vaginal birth; 
severe hypertension; haemolysis, elevated liver enzymes, 
and low platelets (HELLP) syndrome; vomiting; diarrhoea; 
fever; antibiotic use; post-partum haemorrhage; and 
serious maternal complications, including admission to 
the intensive care unit, septicaemia, pulmonary oedema, 
cerebral haemorrhage or oedema, renal failure, eclampsia, 
and maternal death.
Women’s expectations about labour were assessed 
before the induction process. 48 h after the birth, another 
questionnaire assessed their opinions about their 
experience, issues surrounding the induction (including 
time to induction), and their satisfaction with the actual 
labour. Women were asked to rate their overall experience 
on a categorical 5 point scale from very unsatisfied to 
very satisfied. Outcomes were assessed by the treating 
clinician and recorded by a research assistant, neither of 
whom was masked to group allocation.
Fetal or neonatal complications assessed included 
meconium-stained liquor, Apgar score of less than 5 
at 5 min, admission to the neonatal intensive care unit, 
seizures, birth asphyxia (defined as evidence of antenatal 
compromise [meconium-stained liquor or fetal heart-rate 
abnormality] and neonatal compromise [intubation or 
Apgar score <5 at 5 min] and encephalopathy), clinically 
diagnosed septicaemia (defined as use of antibiotics for 
treatment of infection), and stillbirth. Upon discharge, 
babies admitted to the special care unit were assessed for 
encephalopathy by the managing neonatologist, and the 
components of the original Sarnat score were recorded.14 
The score for each baby was assessed by an expert, masked 
to allocation, who judged the presence of encephalopathy 
according to a modified Sarnat score.15 Economic data 
were also collected and will be reported elsewhere.
Statistical analysis
We created a detailed statistical analysis plan with 
dummy tables before data analysis. The statistical 
analysis plan lists all the outcomes to be collected but 
does not exactly match the outcomes in the protocol. The 
comprehensive list of outcomes was contained within 
the case report form and was approved by the ethics 
committee. Sample size was estimated a priori based on 
the primary outcome, assuming a vaginal birth rate of 
41% with the Foley catheter on the basis of previously 
published data using the same induction protocol and 
outcomes as this study.16–18 Detection of an absolute 
increase in this rate to 55% or more (ie, a proportional 
increase of ≥33%), with 90% power and a conventional 
(two-sided) α level of 0·05, required a total sample size 
of 546 evaluable women (n=273 per group). To allow for 
possible losses to follow-up, this number was increased 
by 10%, giving an actual sample size of 602 women 
(n=301 per group). The data monitoring committee 
reviewed the results of one planned interim analysis 
after half the participants were enrolled, with vaginal 
birth within 24 h as the primary outcome of interest. 
Haybittle–Peto boundaries were adopted and the 
committee concluded that the enrolment should 
continue.
Generalised linear modelling (regression) methods 
were used when possible to estimate effect sizes, with 
their corresponding 95% CIs. Binomial regression was 
used for the primary outcome measure (difference in the 
absolute risk of vaginal birth within 24 h) and other 
binary categorical measures, whereas multinomial 
regression was used for multicategory variables. Fisher’s 
exact tests were used in the presence of zero or very small 
frequency counts. We analysed continuous measures 
using linear regression with mean differences or by 
Mann–Whitney U tests with median differences, 
according to their distributions. Women were asked to 
rate their expected (before labour) and experienced levels 
of both pain and anxiety, so the observed differences 
in experienced levels were covariate adjusted for 
the corresponding expected levels. We constructed 
cumulative frequency curves to compare the time course 
of induction to delivery in the two study groups.
We did exploratory subgroup analyses of whether 
attempts to save the fetus would include caesarean 
section in an emergency or not (determined before 
randomisation), parity (nulliparous vs not), site of birth, 
and Bishop score (<6 vs ≥6). Analyses were by intention 
to treat. We used SPSS version 22 plus the cendif 
command in Stata version 13 to obtain confidence 
intervals for median differences.
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Role of the funding source
The study was funded by the UK Department for 
International Development, Medical Research Council, 
and Wellcome Trust Joint Global Health Trials Scheme. 
The funder of the study had no role in data collection, 
data analysis, data interpretation, or writing of the 
report. Their only involvement was to approve the 
membership of the trial steering committee (on which 
they had one representative) and to comment on the 
application when submitted. All authors had full access 
to all the data in the study and the corresponding author 
had final responsibility for the decision to submit for 
publication.
Results
Between Dec 20, 2013, and June 29, 2015, we randomly 
assigned 602 women to the Foley catheter group (n=300) 
or the misoprostol group (302; figure 1). Four women 
(1%) in the Foley group had either a failure of placement 
of the Foley or immediate expulsion of the catheter; three 
of these women were induced with misoprostol 
(two vaginally and one orally) and one was induced with 
oxytocin (figure 1). One woman (<1%) in the Foley group 
withdrew her consent for induction after randomisation 
and had caesarean section (figure 1). All these women 
were included in the final analysis under the intention-
to-treat principle.
No values were missing for the primary outcome. 
However, for the primary and secondary outcomes, 
postnatal measurements were not recorded for two babies 
(<1%) who were stillborn, discharge measurements were 
not registered for the 11 babies (2%) who died before 
discharge, and age at first oral feed was not recorded for 
two babies (<1%) in the Foley group and eight babies 
(1%) in the misoprostol group.
Baseline characteristics were similar between groups 
(table 1). Most women were nulliparous with a median 
gestational age of 39 weeks (table 1). At enrolment, mean 
systolic blood pressure was 142·5 mm Hg (SD 11·9) and 
diastolic blood pressure was 94·9 mm Hg (8·3), with 
virtually all women (96%) receiving antihypertensive 
medication (table 1). 15% of women in the Foley catheter 
group and 14% of those in the misoprostol group had 
received magnesium sulphate in the 12 h before study 
enrolment (table 1). No HIV-positive women were 
assessed in the study.
The primary outcome of vaginal birth within 24 h was 
significantly more common in women in the misoprostol 
group than in those in the Foley catheter group 
(172 [57·0%] vs 141 [47·0%] women; absolute risk 
difference 10·0%, 95% CI 2·0–17·9; p=0·0136 table 2). 
The mean time from induction to delivery was shorter in 
the misoprostol group than in the Foley catheter group 
(table 3, figure 2). Women induced with misoprostol were 
more likely to have a vaginal birth than those induced with 
a Foley catheter (table 2). Most caesarean sections were 
done because of failure to progress in the first stage of 
labour, which occurred more often in the Foley group, 
whereas more women in the misoprostol group had a 
caesarean section as a result of meconium-stained liquor 
(table 2).
The median time from induction to oxytocin infusion 
was significantly shorter in the Foley catheter group than 
in the misoprostol group, and the median duration of the 
infusion was longer (table 2). Membranes were ruptured 
artificially more often when a Foley catheter was used 
than when misoprostol was given (table 2).
Rates of uterine hyperstimulation were low in both 
groups, as were rates of fetal heart-rate abnormality, 
severe hypertension, and use of blood products after trial 
entry (table 2). One woman (<1%) induced with the Foley 
catheter had an intrapartum convulsion and was treated 
with magnesium sulphate. Another woman (<1%) 
induced with the Foley catheter delivered vaginally, 
and was diagnosed with disseminated intravascular 
coagulation and received blood products after birth. Both 
women were discharged in good condition. Four women 
(1%) induced with the Foley catheter were treated for a 
clinical (wound) infection after the start of the trial. No 
women were admitted to the intensive care unit or had 
septicaemia, pulmonary oedema, cerebral oedema or 
haemorrhage, renal failure, uterine rupture, or died.
Two babies (1%) were stillborn to women induced with 
the Foley catheter (table 4). Neonatal morbidity was 
similar in babies born to women in both groups, as was 
the number of babies admitted to the special care 
nursery or the number who received oxygen in the 
2412 patients assessed for eligibility
300 assigned to Foley catheter group
4 failed inductions
 2 bleeds after insertion; Foley expelled 
  immediately
 1 membrane ruptured after insertion of Foley; 
  Foley expelled out
 1 cervix posteriorly placed
1  uncooperative for Foley catheter insertion*
302 assigned to misoprostol group
295 used assigned treatment 302 used assigned treatment 
300 included in intention-to-treat analysis 302 included in intention-to-treat analysis
602 randomly assigned
1810 ineligible
Figure 1: Trial profile
*One woman withdrew her consent for induction after being randomly assigned and underwent caesarean 
section.
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special care nursery (table 4). In the misoprostol group, 
the median time from birth to admission was only 
17 min and median length of stay only 49 min (table 4), 
reflecting a high number of babies who were seen for 
brief assessment only. The time from birth to admission 
to the special care nursery was longer for babies born 
following induction with the Foley catheter, but median 
length of stay was similar between groups (table 4). 
Neither the proportion of babies with a completed Sarnat 
score nor the grades of the scores differed significantly 
between groups (appendix). Nine babies (1%) died: three 
in the Foley group (all due to prematurity) and six in the 
misoprostol group (three due to prematurity, one from 
prematurity plus intrauterine growth restriction, one 
from intrauterine growth restriction alone, and one 
from asphyxia). The causes of death did not differ 
significantly between the two groups.
17 serious adverse events (3%) were reported during 
the study. In addition to the one woman who had an 
intrapartum convulsion and the woman with 
disseminated intravascular coagulation (both in the Foley 
group), we recorded ten incidents of perinatal death (two 
stillbirths in the Foley group and eight neonatal deaths 
[five in the misoprostol group and three in the Foley 
group]) and five incidents of neonatal morbidity, 
comprising birth asphyxia (n=3), septicaemia (n=1), and 
neonatal convulsions (n=1), reported as serious adverse 
events. One neonatal death and one case of septicaemia 
were not reported as severe adverse events.
Most women in both groups found their assigned 
method of induction, and the duration of the induction, 
to be acceptable, and the pain they experienced to be 
either slight or moderate (appendix). More women in the 
misoprostol group than the Foley catheter group would 
use the same method in the future should they require 
another induction (table 2).
In the prespecified subgroup analysis, we identified 
few differences in outcomes between nulliparous and 
parous women (appendix). As expected, parous women 
delivered more quickly and required fewer caesarean 
sections, but these outcomes no longer differed 
significantly between the Foley catheter and misoprostol 
groups (appendix). The need for oxytocin augmentation 
remained significantly higher in the Foley group than the 
Foley catheter 
(n=300)
Misoprostol 
(n=302)
Study site
Government Medical College 150 (50%) 151 (50%)
Daga Women’s Hospital 150 (50%) 151 (50%)
Age, years
Mean (SD) 24·0 (3·5) 23·7 (3·1)
Median (range) 23 (18–42) 23 (18–37)
Mother’s education
No formal education 5 (2%) 2 (1%)
Primary 86 (29%) 112 (37%)
Secondary 149 (50%) 131 (43%)
University 60 (20%) 57 (19%)
Mother’s employment
Farming or manual work 16 (5%) 10 (3%)
Professional, office job, or 
business
6 (2%) 3 (1%)
Housewife 277 (92%) 288 (95%)
Other 1 (<1%) 1 (<1%)
Medical history
Nulliparous (no previous 
pregnancies >28 weeks)
247 (82%) 236 (78%)
Previous caesarean section 0 0
Previous hypertension in 
pregnancy
8 (3%) 16 (5%)
Previous stillbirth 1 (<1%) 5 (2%)
Pre-existing conditions
Diabetes, renal disease, or liver 
disease
0 0
Chronic hypertension 0 1 (<1%)
(Table 1 continues in next column)
Foley catheter 
(n=300)
Misoprostol 
(n=302)
(Continued from previous column
State at recruitment
Booking status
Booked 277 (92%) 284 (94%)
Gestational age (best estimate in 
weeks)
39 (29–42) 39 (29–41)
Estimate made by ultrasound at 
<20 weeks
131 (44%) 127 (42%)
Gestation of ≥37 weeks 241 (80%) 234 (77%) 
Gestation of 32–36+6 weeks 56 (19%) 66 (22%)
Gestation of 28–31+6 weeks 3 (1%) 2 (1%)
Gestation of <28 weeks 0 0
Systolic blood pressure, mm Hg
Mean (SD) 142·2 (11·3) 142·8 (12·5)
Median (range) 140 (104–180) 140 (102–190)
Diastolic blood pressure, mm Hg
Mean (SD) 95·0 (8·3) 94·7 (8·3)
Median (range) 97 (60–130) 90 (66–120)
Proteinuria at enrolment*
0 or trace 156 (52%) 162 (54%)
+1 or +2 122 (41%) 121 (40%)
+3 or +4 22 (7%) 19 (6%)
Hypertensive symptoms at 
enrolment
64 (21%) 58 (19%)
Received magnesium sulphate in 
last 12 h
45 (15%) 42 (14%)
Currently on antihypertensives 292 (97%) 289 (96%)
Time from admission to randomisation, h
Median (IQR; range) 4 (1–13;
0–335)
3·5 (1–10; 
0–849)
Data are n (%), mean (SD), median (range), or median (IQR; range), unless 
otherwise stated.*Detected on urinary dipstick.
Table 1: Baseline characteristics
See Online for appendix
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misoprostol group for both parous and nulliparous 
subgroups (appendix). In parous women, the number of 
babies admitted to the special care nursery was 
significantly higher in the misoprostol group than the 
Foley catheter group (appendix). The cause of admission 
was largely for assessment and observation in babies that 
were of low birthweight, premature, or had meconium 
staining of the liquor. Analysis of the remaining 
subgroups was uninformative. Subgroup analysis by 
study centre showed no important differences between 
groups, and the number of participants was too low for 
analysis by viability or Bishop score (appendix).
Discussion
Our findings show that women undergoing labour 
induction with oral misoprostol had a quicker labour, were 
more likely to have a vaginal birth, and were more satisfied 
than those induced with the Foley catheter. Rates of uterine 
hyperstimulation were low in both groups and neonatal 
morbidity did not differ between groups.
Although both methods had been shown to have 
advantages over other induction methods in systematic 
reviews,5,8,19 until recently, neither had ever been directly 
compared. Ten Eikelder and colleagues10,11 compared the 
30 mL Foley catheter with 50 µg oral misoprostol given 
every 4 h and found no difference in the prevalence of 
caesarean section, hyperstimulation, or adverse neonatal 
outcomes. Participants induced with misoprostol had a 
higher rate of instrumental vaginal births, a lower rate of 
caesarean section for failure to progress in the first stage 
of labour, and were more satisfied than those induced 
with a Foley catheter. That study is not directly 
comparable with ours because of the different oral 
misoprostol regimens, but supports the suggestion that 
oral misoprostol results in fewer caesarean sections and 
greater satisfaction.
Foley catheter (n=300) Misoprostol (n=302) Absolute difference (95% CI) p value
Vaginal birth within 24 h 141 (47·0%) 172 (57·0%) 10·0% (–2·0 to 17·9) 0·0136*
Delivered within 24 h 268 (89·3%) 279 (92·4%) 3·1% (–1·5 to 7·6) 0·194*
Vaginal births
All 149 (49·7%) 178 (58·9%) 9·3% (1·3 to 17·2) 0·0212*
Within 12 h 89 (29·7%) 104 (34·4%) 4·8% (–2·7 to 12·2) 0·209*
Mode of birth
Spontaneous vaginal birth 146 (48·7%) 176 (58·3%) 9·6% (1·7 to 17·5) 0·0194*
Forceps or vacuum birth 3 (1·0%) 2 (0·7%) –0·3% (–1·8 to 1·1) ··
Caesarean section 151 (50·3%) 124 (41·1%) –9·2% (–17·2 to –1·3) ··
Caesarean section indications
Failure to progress first stage of labour 89/151 (58·9%) 53/124 (42·7%) –16·2% (–27·9 to –4·5) 0·0068*
Failure to progress second stage of labour 1/151 (0·7%) 3/124 (2·4%) 1·8% ( –1·2 to 4·8) 0·251*
Fetal heart-rate abnormality 40/151 (26·5%) 41/124 (33·1%) 6·6% ( –4·3 to 17·4) 0·236*
Maternal deterioration 5/151 (3·3%) 0 –3·3% ( –6·5 to –0·1) 0·066*
Intrapartum haemorrhage 3/151 (2·0%) 0 –2·0% ( –4·5 to 0·5) 0·255*
Cord presentation or prolapse 2/151 (1·3%) 2/124 ( 1·6%) 0·3% (–2·6 to 3·2) 0·844*
Meconium-stained liquor 22/151 (14·6%) 38/124 (30·6%) 16·1% (6·2 to 26·0) 0·0014*
Analgesia
Spinal anaesthesia 150 (50·0%) 124 (41·1%) –8·9% (–16·9 to –1·0) 0·0275*
Local anaesthesia 94 (31·3%) 114 (37·7%) 6·4% ( –1·2 to 14·0) 0·097*
Complications of labour and birth
Uterine hyperstimulation 1 (0·3%) 2 (0·7%) 0·3% (–0·8 to 1·5) 0·566*
Fetal heart-rate abnormality 17 (5·7%) 12 (4·0%) –1·7% (–5·1 to 1·7) 0·332*
Diagnosis of post-partum haemorrhage 2 (0·7%) 2 (0·7%) 0 (–1·3 to 1·3) 0·995*
Blood products after trial entry 5 (1·7%) 1 (0·3%) –1·3% (–2·9 to 0·3) 0·099*
Severe hypertension 21 (7·0%) 23 (7·6%) 0·6% (–3·5 to 4·8) 0·772*
Any form of complication 44 (14·7%) 37 (12·3%) –2·4% (–7·9 to 3·0) 0·385*
Would use same method for future induction
Yes 216 (72·0%) 250 (82·8%) ·· ··
No 59 (19·7%) 35 (11·6%) ·· 0·0063†
No preference 25 (8·3%) 17/302 (6%) ·· ··
Time from birth to discharge, h 148 (8–1341) 122 (17–559) –4 (–13 to 3)‡ 0·296§
Data are n (%), n/N (%), or median (range). *Binomial regression. †Fisher’s exact test. ‡Median difference. §Mann–Whitney U test.
Table 2: Birth outcomes
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Our study has some limitations. We recruited women 
on the basis of rapid clinical assessment rather than 
strict international criteria for pregnancy hypertension. 
In busy public hospitals in low-income and middle-
income countries, pragmatic management decisions 
need to be made on the basis of rapid clinical 
assessments, often without the benefit of biochemical 
tests, urinalysis, or inpatient observation. As such, some 
women did not eventually fulfil the formal definition of 
pre-eclampsia because they did not have proven 
proteinuria; other women’s blood pressure settled while 
they awaited randomisation and induction. Although 
this method of recruitment makes the population less 
specific to the treatment of hypertensive disease, it does 
increase the generalisability of the findings, making 
them more applicable to other similar settings and to 
women undergoing labour inductions for other 
indications.
Foley catheter (n=299)* Misoprostol (n=302) Absolute difference (95% CI) p value
Bishop score at recruitment
0–3 118 (39·5%) 115 (38·1%) ·· ··
4–6 181 (60·5%) 187 (61·9%) ·· ··
Mean (SD) 3·52 (1·29) 3·61 (1·13) 0·09 (–0·10 to 0·29) 0·643†
Cervical dilatation at recruitment, cm
0–1 242 (80·9%) 198 (65·6%) ·· ··
1·5–3 57 (19·17%) 104 (34·4%) ·· ··
Mean (SD) 1·03 (0·60) 1·22 (0·66) 0·19 (0·09 to 0·30) <0·0001†
Oxytocin given 244 (81·6%) 157 (52·0%) –29·6% (–36·8 to –22·5) <0·0001‡
Time from randomisation to induction, min
0–59 281 (94·0%) 301 (99·7%) ·· ··
60–119 11 (3·7%) 0 ·· ··
120–179 6 (2·0%) 1 (0·3%) ·· ··
≥180 1 (0·3%) 0 ·· ··
Median (range) 15 (10–27) 5 (5–15) 10 (5 to 10) <0·0001§
Time from induction to oxytocin infusion, min 360 (20–1230) 555 (75–1350) 150¶ (95 to 210) <0·0001§
Duration of oxytocin infusion, min 366 (20–2400) 250 (20–1300) –125¶ (82 to 175) <0·0001§
Time from induction to birth, min
All women
Mean (SD) 861 (468) 771 (421) –90 (–161 to –19) 0·0134†
Median (range) 785 (78–2490) 684 (90–2340) ·· ··
Vaginal deliveries only
Mean (SD) 703 (365) 701 (378) –2 (–82 to 79) 0·967†
Median (range) 660 (120–2100) 633 (90–2155) ·· ··
Caesarean sections only
Mean (SD) 1018 (505) 872 (458) –146 (–261 to –31) 0·0128†
Median (range) 980 (78–2490) 830 (155–2340) ·· ··
No cervical change
At 12 h 1 (0·3%) 1 (0·3%) 0 (–0·9 to 0·9) 1·000‡
At 24 h 0 0 0 1·000‡
Membrane rupture time recorded 250 (83·6%) 252 (83·4%) –0·2% (–6·1 to 5·8) 0·956‡
Membrane ruptured artificially 193/250 (77·2%) 153/252 (60·7%) –16·5% (–24·4 to –8·5) <0·0001‡
Side-effects during induction
Mild diarrhoea 2 (0·7%) 7 (2·3%) 1·7% (–0·3 to 3·6) 0·094‡
Vomiting ·· ·· 1·3% (–2·2 to 4·8)|| 0·465‡
Mild 12 (4·0%) 12 (4·0%) ·· ··
Moderate 1 (0·3%) 5 (1·7%) ·· ··
Data are n (%), mean (SD), median (range), or n/N (%). *No induction data recorded for one participant who refused to have a Foley catheter inserted and so did not deliver 
vaginally. †Linear regression. ‡Binomial regression. §Mann–Whitney U test. ¶Median difference. ||Mild and moderate categories combined.
Table 3: Induction outcomes
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The study was not masked because of the ethical and 
logistical difficulties of doing sham cervical catherisation, 
which increases the risk of bias. However, at the start of 
the study both oral misoprostol and transcervical Foley 
catheterisation were rarely in use at the participating 
hospitals, so clinicians were unlikely to have established 
opinions as to their relative efficacy to affect decision 
making. Thus, we believe that the open-label design of 
the study would not have had major effects on outcomes.
Induction of labour can be hazardous, especially in 
settings without electronic oxytocin infusion pumps and 
few facilities for fetal monitoring. The danger comes 
from the difficulty of balancing inadequate stimulation 
(safe, but with slow labours and high rates of failure) and 
hyperstimulation (rapid labours, but with high rates of 
fetal hypoxia). Additionally, the situation is complicated 
by interpersonal variation in sensitivity to the induction 
drugs. Induction with the Foley catheter has the 
advantage of not directly causing uterine contractions 
during the cervical ripening phase. Typically, however, 
80% of women then need to proceed to an oxytocin 
infusion, which, in settings without electronic infusion 
pumps, can be the most dangerous part of the induction 
process for the fetus. In 1974, Flack and Whyte20 reported 
the wide fluctuations in infusion rates that occur when 
manual drip counters are used. Furthermore, the 
intrapartum use of oxytocin in low-income settings is 
closely associated with neonatal morbidity and mortality, 
and uterine rupture.21 Therefore, the safety benefits of 
the Foley catheter for cervical ripening could be 
neutralised by the dangers of the oxytocin infusion. 
Conversely, oral misoprostol causes both uterine 
contractions and cervical ripening. As a result, more 
women progress through to vaginal birth without 
requiring an oxytocin infusion, which has potential 
safety benefits.
Although neonatal morbidity did not differ significantly 
between the two treatment groups, this study had 
insufficient power to detect anything other than major 
differences in rare outcomes. Babies born to women in 
the misoprostol group more often had meconium-
stained liquor, which was also a common cause of 
caesarean section in that group, accounting for roughly a 
third of all caesarean sections (compared with 15% in the 
Foley catheter group). Meconium-stained liquor is a 
common finding in labours induced with misoprostol, 
and is believed to occur because of stimulation of fetal 
intestinal smooth muscle. In settings without access to 
electronic fetal monitoring, meconium-stained liquor is 
an important clinical sign of fetal compromise and so 
might, in itself, be an indication for caesarean sections in 
these high-risk inductions. Although not associated with 
fetal hypoxia, meconium-stained liquor does carry risks 
of meconium aspiration and so can cause clinically 
significant neonatal morbidity. If electronic fetal 
monitoring were to be introduced for women with 
meconium-stained liquor, then the rate of caesarean 
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Figure 2: Cumulative frequency curves showing time from onset of induction to delivery
All mothers were followed up until delivery, so these curves have no censored observations.
Foley catheter 
(n=300)
Misoprostol 
(n=302)
Absolute difference 
(95% CI)
p value
Outcome of birth ·· ·· ·· 0·248*
Livebirth 298 (99·3%) 302 (100·0%) 0·7%† ··
Stillbirth 2 (0·7%) 0 ·· ··
Birthweight, g ·· ·· ·· 0·918‡
Mean (SD) 2612 (464) 2616 (490) 4 (–72 to 80) ··
Median (range) 2600 (1000–3830) 2600 (750–3800) ·· ··
Apgar score
At 1 min ·· ·· ·· 0·687§
<7 10/298 (3·4%) 12 (4·0%) 0·6% (–2·4 to 3·6) ··
≥7 288/298 (96·6%) 290 (96·0%) ·· ··
At 5 min ·· ·· ·· 0·058§
<7 1/298 (0·3%) 6 (2·0%) 1·7% (–0·1 to 3·4) ..
≥7 297/298 (99·7%) 296 (98·0%) ·· ..
At 10 min ·· ·· ·· 0·431*
<7 0 5 (1·7%) 1·7%† ··
≥7 298/298 (100·0%) 297 (98·0%) ·· ··
Median age at first oral 
feed, min (IQR; range)¶
57 (35–90; 
1–18 720)
50 (30–90; 
<1–3000)
0 (–540 to 300)|| 0·524**
·· ··
Median age at first gasp, 
s (IQR; range)††
5 (4–6; 2–20) 5 (4–6; 2–120) 0 ( –1 to 0)|| 0·060**
·· ··
Median age at heart rate 
>100 beats per min, s 
(IQR; range)¶
5 (4–6; 2–20) 6 (4–7; 2–150) 0 (0 to 0)|| 0·103**
·· ··
Worst consciousness 
level between 30 min 
and 72 h
·· ·· ·· 0·628*
Normal 294/298 (98·7%) 293 (97·0%) ·· ··
Hyperalert 0 1 (0·3%) ·· ··
Reduced but rousable 3/298 (1·0%) 6 (2·0%) ·· ··
Unrousable 1/298 (0·3%) 2 (0·7%) ·· ··
(Table 4 continues on next page)
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section could be reduced further in the misoprostol 
group, increasing the difference between the two 
treatments.
In settings with electronic infusion pumps, oxytocin 
infusions have an advantage over vaginal induction agents 
because they produce a very reliable infusion rate and can 
be stopped rapidly in the event of hyperstimulation or 
abnormalities in fetal heart rate. The short half-life of 
oxytocin means that the effect wears off within minutes. 
By contrast, vaginal misoprostol tablets last for many 
hours and cannot be removed, which complicates 
management of hyperstimulation or suspected fetal 
hypoxia. The production of misoprostol as a vaginal insert 
has improved this problem, enabling rapid removal of the 
drug from the vagina. However, the inserts are expensive 
and scarcely available in low-resource settings. Oral 
misoprostol is rapidly absorbed with a peak serum 
concentration of 30 min, and is largely metabolised by 
120 min,22 thus requiring a frequent dosing regimen of 
1–2 h. Although this regimen could be deemed 
inconvenient, it does mean that a woman will be monitored 
frequently during the induction process and cannot just be 
given the drug and reviewed 4–6 h later. Furthermore, if a 
woman starts to experience hyperstimulation, the next 
dose can be omitted leading to a reduction in contractions 
within a short space of time. In a low-resource setting with 
few staff, this regimen is a little more resource intensive, 
but potentially safer.
The absence of electronic fetal monitoring is typical of 
many public hospitals in low-income and middle-income 
countries, and has important implications for the study 
outcomes. In low-risk pregnancies, electronic fetal 
monitoring is associated with increased operative 
intervention, whereas in high-risk pregnancies it might 
have the effect of reassuring clinicians about fetal health, 
thus preventing intervention (eg, for meconium-stained 
liquor). However, the lack of electronic fetal monitoring 
might make it more difficult to diagnose uterine 
hyperstimulation and therefore lead to a worsening of 
fetal outcomes. Certainly, in this study, the rates of 
hyperstimulation were unusually low compared with the 
usual rates of about 5%.5 In our study, attending staff 
constantly monitored contraction frequency and formally 
recorded it every 2 h, but there remains the possibility 
of underdiagnosis. The absence of electronic fetal 
monitoring means that contraction assessment could not 
be checked retrospectively or be masked, increasing the 
risk of bias.
In the parous subgroup of this study, we recorded more 
admissions to the special care nursery in the misoprostol 
group than the Foley catheter group. This finding reflects 
the excess of premature babies recruited in the 
misoprostol group, as well as the higher rate of 
meconium-liquor staining in that group, which is thought 
to relate to a direct smooth muscle effect of misoprostol 
on the fetal intestine and has not been associated with 
fetal hypoxia.5 Most babies stayed in the special care 
nursery for less than an hour, reflecting their routine 
transfer for assessment only. This outcome is supported 
by the finding that the time to transfer to the special care 
nursery was also lower in the misoprostol group than the 
Foley catheter group.
Many previous studies5 of oral misoprostol have given 
misoprostol every 4–6 h, similar to vaginal misoprostol. 
Conversely, our study used a 2-h dosing regimen, which 
is more consistent with the pharmacokinetics of oral 
misoprostol,22 and is the first oral misoprostol study to 
use 25 µg misoprostol tablets. Previous studies5 have 
either used divided 100–200 µg tablets, which can lead to 
inaccuracies because the tablets can shatter and crumble, 
or oral misoprostol solution, for which the stability is 
uncertain. The 25 µg tablets should provide a stable and 
consistent form for the future.
Foley catheter 
(n=300)
Misoprostol 
(n=302)
Absolute difference 
(95% CI)
p value
(Continued from previous page)
Neonatal death 3/298 (1·0%) 6 (2·0%) 1·0% (–1·04 to 2·97) 0·322§
Neonatal morbidity ·· ·· ·· 0·226*
No morbidity 286/298 (96·0%) 289 (95·7%) ·· ··
Meconium-stained 
liquor
6/298 (2·0%) 10 (3·3%) ·· ··
Neonatal convulsions 0 1 (0·3%)‡‡ ·· ··
Birth asphyxia 2/298 (0·7%) 1 (0·3%) ·· ··
Septicaemia 1/298 (0·3%) 1 (0·3%) ·· ··
Other 3/298 (1·3%)§§ 0 ·· ··
Baby admitted to special 
care nursery
19/298 (6·4%) 28 (9·3%) 2·9% (–1·4 to 7·2) 0·186§
Median time from birth 
to special care nursery 
admission, min 
(IQR; range)
25 (11–1175; 
5–4930)
17 (10–34; 
0–3940)
–10 ( –60 to 3)|| 0·072**
Median time from special 
care nursery admission to 
discharge, min 
(IQR; range)
51 (20–111; 
14–1340)
49 
(23–85; 0–525)
–3 ( –38 to 22)|| 0·795**
Baby given oxygen 33/298 (11·1%) 42 (13·9%) 2·8 (–2·5 to 8·1) 0·293§
Median length of oxygen 
administration, min 
(IQR; range)
30 
(10–240; 5–14 400)
60 
(10–720; <1–4320)
30 (–60 to 540)|| 0·481**
·· ··
Baby ventilated 4/298 (1·3%) 4 (1·3%) 0 (–1·9 to 1·8) 0·985§
Median length of 
ventilation, h 
(IQR; range)
27 
(2–156; 0·5–192)
65·5 
(15–72; 0·2–72)
17 (–133 to 72)|| 0·886**
Sarnat score completed 19/298 (6·3%) 29 (9·6%) 3·3% (–1·0 to 7·6) 0·138§
Revised Sarnat score ·· ·· ·· 1·000*
Normal 13/19 (68·4%) 20/29 (69·0%) ·· ··
Moderate 6/19 (31·6%) 8/29 (27·6%) ·· ··
Severe 0 1/29 (3·4%) ·· ··
Data are n (%), mean (SD), median (range), n/N (%), or median (IQR; range). *Fisher’s exact test. †95% CI not 
calculable. ‡Linear regression. §Binomial regression. ¶Not recorded for two babies in Foley catheter group and eight 
babies in misoprostol group. ||Median difference. **Mann–Whitney U test. ††Not recorded for one baby in misoprostol 
group. ‡‡Age was 1090 min. §§One low birthweight, one premature with very low birthweight, and one respiratory 
distress syndrome.
Table 4: Neonatal outcomes
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In the present study, more women in the oral 
misoprostol group than the Foley catheter group would 
use the same method again if they needed induction in 
the future. This outcome is not surprising given that 
women in the Foley group avoided an initial 
uncomfortable vaginal examination in which a catheter 
was inserted into the cervix. Some participants also 
avoided an oxytocin infusion and others avoided a 
caesarean section. Pain experienced did not differ 
between the treatment groups; women in the Foley 
catheter group informally reported discomfort on 
insertion, but then reported being pain free until active 
labour. By contrast, although women in the misoprostol 
group avoided the initial insertion, they often had 
contraction pain during the cervical ripening process. 
These findings are in keeping with those of other Foley 
catheter versus prostaglandin induction studies.11
In some studies, oral misoprostol has been used both 
for cervical ripening and induction, with regular doses of 
oral misoprostol used in place of the oxytocin infusion 
characteristic of most induction protocols. In addition to 
being potentially more satisfying for the woman, this 
procedure also has logistic advantages due to 
misoprostol’s stability in heat and ease of administration. 
In settings in which there are no electronic infusion 
pumps, use of oral misoprostol also ensures a regular 
and standard dose of stimulant. The fear that misoprostol 
could be dangerous to the fetus because of irreversible 
hyperstimulation has not been proven in the studies5 in 
which it has been used. One would expect that oral 
misoprostol used up to birth would be as effective as the 
misoprostol and oxytocin regimen, but potentially safer 
in settings without electronic infusion pumps. However, 
no direct comparisons have been done.
In summary, 25 µg oral misoprostol given every 2 h 
was more effective and more acceptable to women than a 
transcervical Foley catheter for induction of labour in 
women requiring delivery because of pre-eclampsia or 
hypertension. Oral misoprostol also seemed to be safe, 
despite the absence of routine fetal monitoring or 
electronic oxytocin infusion pumps. More studies are 
required to assess whether the oxytocin augmentation 
following misoprostol can be replaced by regular doses of 
oral misoprostol tablets.
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